16:45 – 18:00 Debate: Are pneumococcal conjugate vaccines useful in adults, in the presence of widespread paediatric PCV use in Europe?
Charles Brosch (SE)
• Pro: Marc Bonnant [NL]
• Con: Ron Dagan [IL]

Scientific Programme 7 March 2015
09:00 – 10:45 Safety issues in vaccines – potential risk for mutual protection
Chairpersons: Liyan Tan (US), Pauline Paterson (UK)
• How vaccine confidence in Europe will influence community protection Pauline Paterson (UK)
• Does the unvaccinated population impact the community they live in? Frederic Bouder (NL)
• Does knowledge about mutual protection increase or decrease vaccination behaviour? TBC
11:15 – 13:15 Pertussis protection throughout life – how can we achieve this?
Chairpersons: Stanley Plotkin (US), Carl Heinz Wirsing von König (DE)
• Current schedules in Europe – how many doses throughout lifetime? Stanley Plotkin (US)
• Protection against pertussis in the very young baby...would vaccines, pre-partum maternal immunization or neonatal immunization? Philippe Dudas (WHO)
• Insights from the biology of Bordetella pertussis and vaccine research to new directions Stanley Plotkin (US)
• Live pertussis vaccines – will they provide protection against carriage and spread of pertussis Camille Locht (FR)
14:30 – 16:15 New insights into prevention of viral gastroenteritis in all ages
Chairpersons: Adam Finn (UK), Timo Vakilari (FI)
• Transmission of GIT viral infections – rotavirus and norovirus, potential for hard protection prevention Timo Vakilari (FI)
• Challenges to uptake and optimal performance of rotavirus Vaccines that might impact herd immunity Jumesh Parashar (US)
• Vaccines against norovirus – state art, trails in children and adults Paloma Carrillo-Santisteve (Sweden)
17:15 – 18:30 Can we achieve meningococcal control in Europe?
Chairpersons: Juhani Eskola (FI), Lucio Pasciante-Calentano (ECDC)
• What would be the best schedule for prevention of meningococcal disease in all ages? Ray Boroujerdi (UK)
• Can we control all cause meningococcal disease in Europe? Andrew Pollard (UK)

Scientific Programme 8 March 2015
09:00 – 10:45 Recent threats of poliovirus - did we open the Pandora box?
Chairpersons: Robby Butler (WHO), Liz Miller (UK)
• Rapid spread and control of wild poliovirus in highly IPV-vaccinated population – the Israel experience Jacob Moran-Gilad (IL)
• Is the EU population protected from poliomyelitis? Paloma Carillo-Santisteve (ECDC)
• Do we need to modify our approach to poliopolivus “end of game” including going for a new improved vaccine David Salisburry (UK)
11:15 – 12:30 Debate: Universal VZV vaccination to children
Chairpersons: Ron Dagan (IL), Roman Pygmallo (CZ)
• Pro: Adam Finn (UK)
• Con: Hanna Nohynek (FI)
12:30 – 12:45 Closing Remarks

Faculty
Hugues Bogaerts, Belgium
Paolo Bonanni, Italy
Marc Bonnant, Netherlands
Ray Boroujerdi, United Kingdom
Frederic Bouder, Netherlands
Robbe Burke, Denmark
Paloma Carillo-Santisteve, Sweden
Xavier Castellsapel, Spain
Chris Chiu, United Kingdom
Ron Dagan, Israel
Philippe Dudas, Switzerland
Juhani Eskola, Finland
Susanna Esposito, Italy
Adam Finn, United Kingdom
Elmar Joura, Austria
Keith Klugman, United States
Camille Locht, France
Pier Luigi Lopalco, Sweden
Liz Miller, United Kingdom
Jacob Moran-Gilad, Israel
Hanna Nohynek, Finland
Ake Drlstrup, Sweden
Albert Osterhaus, Netherlands
Umesh Parashar, United States
Lucia Pasciante-Calentano, United Kingdom
Pauline Paterson, United Kingdom
Stanley Plotkin, United States
Marc Poljak, Slovenia
Andrew Pollard, United Kingdom
Roman Pygmallo, Czech Republic
Gusz Rimmelzwaan, Netherlands
David Salisburry, United Kingdom
Marc Sprenger, Sweden
Liyan Tan, United States
Timo Vakilari, Finland
Carl Heinz Wirsing von König, Germany

3rd Conference on Vaccines for Mutual Protection
Lisbon, Portugal 6 – 8 March 2015
P10 Awareness Of Human Papillomavirus (HPV) Infection And Willingness To HPV Vaccination Among Males With Sexually Transmitted Infections

P11 Hepatitis A: Universal Vaccination For Adult Travelers? Sioua Duerte-Roche, Portugal

P12 Epidemiological Evidence Of Invasive Pneumococcal Disease In Adults Following Introduction Of Conjugate Pneumococcal Vaccine

P13 Human Papillomavirus Vaccination In Portugal, October 2008 To June 2014

P14 Barriers And Motivators Of Seasonal Influenza Vaccine Uptake Between Iranian Healthcare Workers During 2012/2013 Season

P15 Effective Hepatitis A Vaccination: A Cost-Effectiveness Study In Italy

P16 Epidemiology Of Adult Pneumococcal Nongenital Infections In The Early Post PCV Era: A Nation-Wide Study, Israel

P17 Colonisation Of The Pharynx By S. pneumoniae In Older Children And Adolescents In An Area Characterised By Limited Pneumococcal Vaccination Coverage

P18 Seroprevalence Of HBV And Knowledge About Hepatitis B Vaccine In Pregnant Women In Spain. Are We Forgetting This High-Risk Group? Lize Meno Wits, Spain

P19 An Analysis Of Government Immunization Program Expenditures In Lower And Lower Middle Income Countries 2006–12

P20 Meningococcal Vaccination Strategy In The Czech Republic

P21 A Randomized, Double-Blind, Phase III Trial To Assess The Immunogenicity And Safety Of NBP606, A New 13-Valent Pneumococcal Conjugate Vaccine

P22 Measles And Rubella Elimination In Italy: Parvovirus B19 In The Differential Diagnosis

P23 Seasonal And Pandemic Influenza Vaccination Coverage In Pregnant Women In Spain: Are We Forgetting This High-Risk Group? Lize Meno Wits, Spain

P24 Evaluation Of The Admission Reasons And The Response Rates Of The HBV Vaccination At The Adult Vaccination Polyclinic, Sukkun Kes, Turkey

P25 Serotypes Of Streptococcus pneumoniae From Children With Tuberculosis And Tubercolosis Hospital Staff

P26 Pneumococcal Conjugate Vaccines - Impact In The Czech Republic

P27 Live Enterovirus Vaccines As Oncolytic Agents Applicable For Cancer Therapy

P28 Recombinant Trichinella spiralis 53kda Protein Directly Activates Macrophages In M2 Pattern

P29 Burden Of Community-Acquired And Nosocomial Infections

P30 Healthcare Workers As Parents And As Professionals: Attitudes Towards Immunization

P31 Risk Factors Associated For Community-Acquired Pneumonia Among Hospitalized Patients: The Risky Stacking Impact

General Information

Networking Evening, 7 March 2015 – 20.00h

The Networking Evening will be celebrated in a restaurant directly at the river front. Transfer from the conference venue will be organized. More information can be found on the invitation.


Organising Committee
Ron Daghn, Israel
Susanna Esposito, Italy
Marco Pavlik, Slovakia

Scientific Secretariat
Ron Daghn
Nora Nedić
ESCMID Executive Office
P.O. Box 254
4010 Basel, Switzerland
Phone: +41 61 508 01 52
Email: escmid2015@escmid.org

Conference Secretariat
Leading – You Congress Organiser
Celia Araujo
Rua Diego Couto, 1 B
2799-377 Línc-a-Velha
Tel: +351 217 712 638
Email: escmid2015@leading.pt

Conference Venue
SANA Lisboa Hotel
Av. Francisco Pereira de Melo, 8
1069-310 Lisbon, Portugal